Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen

AIDS

Volumn 22, Issue 14, 2008, Pages 1809-1813

  Delaugerre, Constance ^a   Pavie, Juliette ^a   Palmer, Pierre ^a   Ghosn, Jade ^b   Blanche, Stephane ^c   Roudiere, Laurent ^c   Dominguez, Stephanie ^d   Mortier, Emmanuel ^e   Molina, Jean Michel ^a   De Truchis, Pierre ^f  

^a SAINT LOUIS HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Mondor Hospital   (France)

^e HÔPITAL LOUIS MOURIER   (France)

^f Raymond Poincare APHP   (France)

Author keywords

(fos)amprenavir; Darunavir; Protease inhibitor cross resistance; Resistance mutations; Tipranavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PYRIDINES; PYRONES; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 66349091714     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328307f24a     Document Type: Article

References (19)

1. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766.
2. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
3. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007; 81:13845-13851.
4. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
5. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46:24-31.
6. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
7. DeJesus E, Ortiz R, Khanlou H, Voronin E, Van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211). 47th ICAAC, Chicago, USA 2007, [abstract H-718b].
8. De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, Van Baelen B, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy. Antivir Ther 2006; S73.
9. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78:153-160.
10. Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008; 52:491-496.
11. De Meyer S, De Paepe E, Vangeneugden T, Van Baelen B, Spinosa-Guzman S, Lefebvre E, et al. Development of resistance in patients with virologic failure on darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r): results of a randomized, controlled, Phase III trial in treatment-experienced patients (TITAN). 47th ICAAC, Chicago, USA 2007, [abstract H-1020].
12. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78:12012-12021.
13. Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007; 196:1177-1179.
14. Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, Gonzalez-Lahoz J, Soriano V. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60:885-888.
15. Delaugerre C, Mathez D, Peytavin G, Berthe H, Long K, GalperineT, deTruchis P. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS 2007; 21:1210-1213.
16. de Mendoza C, Valer L, Bacheler L, Pattery T, Corral A, Soriano V. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 2006; 20:1071-1074.
17. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/ lopinavir-based regimen. AIDS 2004; 18:1965-1966.
18. Picchio G, Vangeneugden T, Van Baelen B, Lefebvre E, Miralles D, de Bethune MP. Prior utilization/resistance to amprenavir at screening has minimal impact on the 48-response to darunavir/ r in the POWER 1, 2 and 3 studies. 14th CROI, Los Angeles, USA, 2007, [abstract 609].
19. De Meyer S, Picchio G, Vangeneugden T, Spinosa-Guzman S, Lathouwers E, de Bethune MP. Impact of high baseline resistance to approved protease inhibitors on darunavir/r virologic response in treatment-experienced patients in POWER 1,2 and 3. Antivir Ther 2007; 12:S89.